Healio

Phase 3 trial of phentolamine for presbyopia achieves primary, secondary endpoints

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A second phase 3 pivotal clinical trial investigating ...
Nasdaq

Opus Genetics Reports Positive Phase 3 Results for Phentolamine Ophthalmic Solution in Treating Night Driving Impairment in Keratorefractive Patients

Opus Genetics, Inc. announced positive results from its Phase 3 clinical trial, LYNX-2, which evaluated Phentolamine Ophthalmic Solution 0.75% for treating chronic night driving impairment in ...
Seeking Alpha

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule ...
Nasdaq

Opus Genetics Announces Positive Topline Results from Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...